Liraglutide and Semaglutide, a weekly GLP- 1 receptor agonist, was finally approved for both indications
Overall, out of 304 participants, 282 (92.8%) concluded the trial by attending the end-of-trial safety evaluation, 272 (89.5%) underwent body weight assessment at the week 104 end-of-treatment visit to determine the long term effects of semaglutide, and 243 (79.9%) adhered to the treatment protocol until the end-of-treatment visit (Fig
For Group B, weight loss was likely negated by the weight gain effects of insulin
Regular follow-up appointments allow healthcare providers to assess gastrointestinal tolerability, adjust management strategies, and ensure that the benefits of tirzepatide therapy continue to outweigh any adverse effects
Lttl says members may cancel through their accounts
She was not involved in the new study and has done consulting work for Novo Nordisk, the pharmaceutical company that makes Ozempic and Wegovy